HORSHAM, Pa. & WASHINGTON--(BUSINESS WIRE)--DIA today announced with FDLI (The Food and Drug Law Institute), distinguishing features of The Future of Biosimilars in the US Conference to be held May 4 - 5, 2011 in Bethesda, Maryland.
“Overview of Biosimilars: Patient Access, Challenges, Statutory Framework Enacted as Part of Affordable Care Act.”
This first-of-its-kind conference will feature perspectives from the US Food and Drug Administration (FDA), as well as industry, lawyers, academics, clinicians, payers and patients on the introduction of biosimilars to the US.
